Evidence map›Paper›PMID 20953381›Full record

ArticleMediators of inflammation2010

The p110α and p110β isoforms of class I phosphatidylinositol 3-kinase are involved in toll-like receptor 5 signaling in epithelial cells.

Sabine M Ivison, Mohammed A S Khan, Nicholas R Graham, Leila A Shobab, Yu Yao, Arnawaz Kifayet, Laura M Sly, Theodore S Steiner

Open access · goldAbstract read
In one paragraph

Article in Mediators of inflammation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sabine M IvisonDivision of Infectious Diseases, Department of Medicine, Vancouver Coastal Research Institute (VCRI), Faculty of Medicin, University of British Columbia, Vancouver, BC, Canada V5Z 3J5.
Mohammed A S Khan
Nicholas R Graham
Leila A Shobab
Yu Yao
Arnawaz Kifayet
Laura M Sly
Theodore S Steiner
Vancouver Coastal Health · CAUniversity of British Columbia · CAChild and Family Research Institute · CA

Funding

CIHRWellcome TrustWellcome Trust 992840.01
6 · The paper itself

Abstract

backgroundBacterial flagellin triggers inflammation in mammalian cells via Toll-like receptor (TLR) 5. Release of the chemokine IL-8 in response to flagellin involves NF-κB, p38 MAP kinase, and phosphatidylinositol 3-kinase (PI3K). However, PI3K has been reported to be either pro- or anti-inflammatory in different model systems. We hypothesized that this could be due to different activities of the p110α and β isoforms of PI3K.

resultsPI3K and Akt were rapidly activated in Caco-2 colon carcinoma cells by flagellin. Using a plasmid-based shRNA delivery system and novel p110 isoform-specific inhibitors, we found that flagellin-induced IL-8 production was dependent on both p110α and p110β. However in the mouse, inhibition of p110β but not p110α reduced the increase of serum IL-6 levels induced by intraperitoneal injection of flagellin.

conclusionsThese data demonstrate that the p110α and β isoforms of class IA PI3K are both required for the proinflammatory response to flagellin.

Indexed as

AnimalsCaco-2 CellsClass Ia Phosphatidylinositol 3-KinaseEpithelial CellsHumansInflammationInterleukin-6Interleukin-8MiceMice, Inbred C57BLPhosphatidylinositol 3-KinasesPromoter Regions, GeneticProtein IsoformsToll-Like Receptor 5Class Ia Phosphatidylinositol 3-KinaseInterleukin-6Interleukin-8Phosphatidylinositol 3-KinasesProtein IsoformsTLR5 protein, humanToll-Like Receptor 5

Identifiers

PMID20953381
PMCPMC2952946
OpenAlexW1970961181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.